Does Centene Corporation Cover Forteo (Teriparatide)?

What Is Forteo and Why Does Its Coverage Matter?

Forteo (teriparatide) is a recombinant fragment of human parathyroid hormone approved by the FDA in November 2002 for treating osteoporosis in postmenopausal women, men with primary or hypogonadal osteoporosis, and patients with glucocorticoid-induced osteoporosis who are at high risk of fracture [1]. Unlike bisphosphonates, which slow bone resorption, teriparatide works anabolically by stimulating new bone formation, making it a distinct therapeutic choice for patients who have already fractured or who have very low bone mineral density (BMD) [2].

Coverage matters because osteoporosis affects an estimated 10.2 million Americans aged 50 and older, and roughly 43 million more have low bone mass that predisposes them to fracture [3]. Hip fractures carry a one-year mortality risk of approximately 20% in older adults [4]. Getting the right medication covered is therefore a direct patient safety issue, not merely a cost question.

Centene Corporation operates across more than 30 states and covers approximately 28 million members through Medicaid, Medicare Advantage, and Affordable Care Act Marketplace plans under brand names including Ambetter, WellCare, and Fidelis Care [5]. Because Centene subsidiaries write their own formularies at the state level, coverage details for Forteo vary by plan and geography, but the overall approval framework is consistent: prior authorization plus step therapy documentation.

Teriparatide binds to the PTH1 receptor on osteoblasts and mediates downstream signaling that increases bone formation, as confirmed by the key Neer et al. trial (N=1,637), which showed vertebral fracture reduction of 65% versus placebo over 21 months (P<0.001) [6]. That clinical evidence base is precisely what payers reference when designing tiered coverage requirements.

How Centene Structures Its Formulary for Specialty Bone Agents

Centene and its subsidiaries place teriparatide on specialty tiers, typically Tier 4 or Tier 5, within most formularies. Specialty tier placement means the drug requires both prior authorization and, in many plans, specialty pharmacy dispensing through a contracted vendor such as CVS Specialty, Walgreens Specialty, or AllianceRx Walgreens Prime.

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines explicitly recommend anabolic therapies like teriparatide for patients at "very high" fracture risk, defined as a T-score below negative 3.0, a recent fracture within 12 months, or multiple fractures on antiresorptive therapy [7]. Payers including Centene frequently embed these exact AACE thresholds into their prior authorization criteria.

Three standard documentation elements that Centene plans routinely request:

1. A dual-energy X-ray absorptiometry (DXA) scan result showing T-score at or below negative 2.5 at the spine or hip, or documented fragility fracture history.
2. Evidence of at least one prior antiresorptive trial. Alendronate 70 mg once weekly for a minimum of 12 months is the most commonly accepted first-line bisphosphonate, though risedronate and zoledronic acid are sometimes accepted [8].
3. A prescriber attestation confirming the patient meets criteria for "high" or "very high" fracture risk, often referencing FRAX score or NOGG/ISCD guidelines.

Without these three elements, the prior authorization request is very likely to be denied on the first submission.

Prior Authorization Requirements in Detail

Prior authorization (PA) for Forteo through any Centene subsidiary plan is non-negotiable for the vast majority of members. The PA form asks prescribers to document specific clinical data points that mirror FDA-approved indications and major society guidelines.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "We suggest using teriparatide or abaloparatide over bisphosphonates in women with very high fracture risk (e.g., older patients with a T-score of negative 2.5 or less at the spine or hip, plus a prior fragility fracture)" [9]. Centene PA reviewers will often cite this exact threshold when evaluating requests.

Specific data the prescriber must typically provide includes:

• Most recent DXA T-score with the date of the scan (scan must usually be within 24 months of the PA request).
• FRAX 10-year probability of major osteoporotic fracture, or a documented prior fragility fracture at the spine, hip, wrist, or humerus.
• Names, doses, and duration of prior bisphosphonate therapy, plus reason for discontinuation or treatment failure. "Inadequate response" is typically defined as continued bone loss (more than 5% BMD decline on serial DXA) or a new fracture despite adherent therapy [10].
• Diagnosis code consistent with osteoporosis (ICD-10: M80 for osteoporosis with current pathological fracture, M81 for osteoporosis without pathological fracture).
• Prescribing physician's NPI and specialty (endocrinology, rheumatology, geriatrics, or primary care with documented bone health expertise is generally accepted).

The initial PA period granted is typically 6 months for Medicaid plans and 12 months for commercial Ambetter plans. Renewals require updated DXA data or a clinical note documenting treatment response.

Step Therapy: The Bisphosphonate Requirement

Step therapy is a managed care strategy requiring patients to try and fail a lower-cost medication before accessing a more expensive one. For Forteo, Centene's step therapy policies nearly universally require at least one bisphosphonate trial. Alendronate sodium 70 mg/week is the most frequently mandated first-line agent [11].

This requirement is grounded in comparative efficacy and cost data. Generic alendronate costs approximately $10 to $15 per month without insurance, while Forteo's AWP exceeds $3,200 per 28-day supply. The FLEX trial (Fracture Intervention Trial Long-term Extension, N=1,099) demonstrated that patients who had received alendronate for five years maintained fracture protection even after discontinuation, supporting bisphosphonate durability [12].

However, some patients are genuinely unable to complete bisphosphonate step therapy. Documented exceptions that Centene plans may accept include:

• Esophageal stricture, achalasia, or inability to remain upright for 30 minutes (contraindication to oral bisphosphonate).
• History of atypical femoral fracture on prior bisphosphonate use.
• Bisphosphonate-related osteonecrosis of the jaw (BRONJ) confirmed by dental or oral surgery records.
• Creatinine clearance below 30 mL/min (most oral bisphosphonates are contraindicated at this level per prescribing information) [13].
• New vertebral fracture occurring while the patient was adherent to bisphosphonate therapy for at least 12 months, demonstrating true treatment failure.

Submitting these contraindication documents upfront with the initial PA request, rather than waiting for a denial, reduces approval time substantially.

What Happens After a Denial: Appeals and Exceptions

If Centene denies a Forteo prior authorization, federal and state law provides members with the right to appeal. For Medicaid managed care plans, the Centers for Medicare and Medicaid Services (CMS) requires that standard appeal decisions be issued within 30 calendar days, and expedited appeals within 72 hours when a physician certifies that the standard timeline would seriously jeopardize health [14].

For Medicare Advantage WellCare plans, the CMS Part D appeals process allows:

• Level 1: Redetermination by the plan (within 7 days for standard, 72 hours for expedited).
• Level 2: Independent Review Entity (IRE) review if the plan upholds the denial.
• Levels 3 through 5: ALJ hearing, Medicare Appeals Council, and Federal District Court for cases meeting dollar thresholds.

A strong appeal includes a peer-reviewed clinical letter from the treating physician citing the Neer et al. fracture reduction data [6], the AACE guideline recommendation for anabolic-first therapy in very high-risk patients [7], and any patient-specific imaging or laboratory data that supports urgency.

The HealthRX clinical team has developed the following five-step documentation checklist for submitting a Forteo PA to any Centene subsidiary with the highest probability of first-pass approval:

Step 1. Obtain a DXA scan within the preceding 24 months showing T-score at or below negative 2.5 at the lumbar spine or total hip, or document a radiographically confirmed fragility fracture.

Step 2. Calculate and record the FRAX 10-year major osteoporotic fracture probability. A score above 20% for major fracture or above 3% for hip fracture meets the National Osteoporosis Foundation threshold for treatment initiation [15].

Step 3. Document 12 months of adherent bisphosphonate therapy (medication possession ratio above 80%) with either a new fracture on therapy, continued BMD loss on serial DXA, or a clinically documented contraindication if step therapy cannot be completed.

Step 4. Write a prescriber letter explicitly citing the Endocrine Society 2019 guideline language ("very high fracture risk") and the AACE 2020 recommendation for anabolic-first therapy, matched to the patient's specific clinical parameters.

Step 5. Submit all documents simultaneously through the plan's specialty pharmacy PA portal, not by fax, to generate a timestamped electronic record and reduce processing delays.

Forteo Coverage Across Specific Centene Subsidiaries

Centene operates under several subsidiary brands, and the formulary for each plan type differs meaningfully.

Ambetter (Marketplace/ACA Plans). Ambetter plans in most states place teriparatide on Tier 4 or Tier 5. PA is required. The step therapy requirement is most commonly a 12-month bisphosphonate trial. Ambetter member cost-sharing after PA approval depends on the metal tier: a Silver plan member may pay a specialty copay of $100 to $150 per 28-day supply after deductible, while a Gold plan member may pay less depending on state-specific benefit design.

WellCare (Medicare Advantage and PDP). WellCare Medicare Advantage formularies list teriparatide as a specialty drug with PA. The CMS Medicare Part D formulary guidelines require that all covered drugs have a cost-sharing cap for low-income subsidy (LIS) beneficiaries, meaning dual-eligible members may pay $0 to $10.35 per fill depending on subsidy level [16]. Under the Inflation Reduction Act's Part D redesign effective 2025, out-of-pocket drug costs for Medicare beneficiaries are capped at $2,000 annually, which materially benefits patients on high-cost specialty agents like Forteo [17].

Medicaid Managed Care Plans. Centene's state Medicaid plans (including Sunshine Health in Florida, Peach State Health in Georgia, and IlliniCare in Illinois, among others) are subject to each state's Medicaid preferred drug list (PDL). Several state Medicaid programs have added biosimilar or lower-cost anabolic agents and may require PA for brand-name Forteo even where generics exist. As of 2024, the FDA has not approved a generic teriparatide; however, biosimilar versions (Bonsity, Tymlos comparator abaloparatide) exist in adjacent categories and may affect formulary positioning [18].

The 2-Year Lifetime Limit and Sequential Therapy Planning

FDA labeling restricts cumulative teriparatide use to 24 months over a patient's lifetime [1]. This limit originated from osteosarcoma findings in rat studies at supraphysiologic doses; the clinical relevance in humans at therapeutic doses remains a subject of ongoing investigation, and no causal link to human osteosarcoma has been established in post-marketing surveillance spanning more than 20 years [19].

Because the 24-month lifetime maximum is hard-coded into FDA labeling, Centene plans enforce it strictly. Once a member reaches 24 months of teriparatide use, no further PA approvals will be issued for the same drug, even with a new clinical rationale.

Sequential therapy planning is therefore essential. The AACE 2020 guideline recommends transitioning patients from anabolic to antiresorptive therapy at the end of the teriparatide course to preserve gains in BMD [7]. Denosumab 60 mg subcutaneously every 6 months or zoledronic acid 5 mg IV annually are the most commonly used transition agents. This transition must be initiated before the final teriparatide injection, not after, because rapid bone loss can occur if a gap exists between anabolic and antiresorptive therapy [20].

Prescribers should plan the transition therapy PA (if applicable) approximately 3 months before the 24-month teriparatide course ends, particularly for Medicaid members whose denosumab coverage may also require prior authorization under Centene plans.

Patient Assistance and Cost-Reduction Options

Even with Centene coverage, member cost-sharing for Forteo can be substantial, particularly for Ambetter commercial plan members who have not met their deductible. Several options exist to reduce out-of-pocket costs.

Lilly Cares Foundation. Eli Lilly's patient assistance program provides Forteo at no cost to uninsured or underinsured patients who meet income eligibility criteria (typically at or below 400% of the federal poverty level for commercial patients) [21]. Enrolled patients receive the medication directly from Lilly.

Lilly's Forteo Savings Card. For commercially insured patients including Ambetter members, Lilly has offered a savings card program that may reduce monthly copays to as low as $25. This program is not available to Medicare or Medicaid beneficiaries under federal anti-kickback statute rules.

State Pharmaceutical Assistance Programs (SPAPs). Several states operate SPAPs that provide supplemental cost-sharing support for Medicare beneficiaries, including WellCare members, who face high specialty drug costs. Eligibility and benefit levels vary by state [22].

340B Program. Patients who receive care at federally qualified health centers (FQHCs), Ryan White clinics, or other 340B-covered entities may access Forteo at significantly reduced 340B ceiling prices. Centene Medicaid members who receive prescriptions through 340B-participating providers may see lower pharmacy costs depending on how the plan's contracting with the 340B entity is structured [23].

Abaloparatide (Tymlos): An Alternative Anabolic Agent on Centene Formularies

Abaloparatide (Tymlos, Radius Health/AbbVie), a synthetic analog of parathyroid hormone-related protein, received FDA approval in April 2017 for postmenopausal osteoporosis at high fracture risk [24]. The ACTIVE trial (N=2,463) demonstrated that abaloparatide 80 mcg/day reduced new vertebral fractures by 86% versus placebo (P<0.001) and produced greater gains in total hip BMD at 18 months compared with teriparatide [25].

Some Centene subsidiary formularies list abaloparatide as the preferred anabolic agent, requiring PA and step therapy failure on bisphosphonates before approving teriparatide, while others treat the two drugs as interchangeable within the anabolic class. Prescribers who encounter a teriparatide denial should verify whether abaloparatide is listed as the preferred anabolic on the member's specific plan formulary, as substituting abaloparatide may reduce PA turnaround time from weeks to days.

Romosozumab (Evenity, Amgen/UCB), a sclerostin inhibitor approved in April 2019 for postmenopausal osteoporosis at high fracture risk, represents a third anabolic option [26]. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced clinical fracture risk by 27% versus alendronate alone (P<0.001) at 24 months [27]. Centene formularies typically place romosozumab on a restricted specialty tier with PA and a cardiovascular risk screening requirement, given the label's boxed warning about myocardial infarction and stroke [26].

Glucocorticoid-Induced Osteoporosis Coverage Nuances

Patients on long-term glucocorticoid therapy (prednisone 5 mg/day or more for 3 or more months) face accelerated bone loss. The ACR 2017 guideline on glucocorticoid-induced osteoporosis recommends anabolic therapy as initial treatment for patients classified as high or very high fracture risk using modified FRAX scoring that accounts for glucocorticoid dose [28].

FDA labeling explicitly includes glucocorticoid-induced osteoporosis as an approved indication for teriparatide [1]. Centene PA criteria for this population typically require documentation of:

• Glucocorticoid dose and duration (prednisone equivalent dose and start date).
• DXA T-score below negative 2.5, or fragility fracture on glucocorticoid therapy, or FRAX score adjusted for glucocorticoid use.
• Prior bisphosphonate trial, unless the prescriber documents a specific contraindication relevant to the glucocorticoid-treated patient (such as severe gastroesophageal reflux precluding oral bisphosphonate use).

The EUROFORS study (N=868) demonstrated that teriparatide produced significantly greater spine BMD gains than continued antiresorptive therapy in glucocorticoid-treated patients with osteoporosis [29]. Citing this trial in the PA letter, alongside ACR guideline language, strengthens the clinical justification for anabolic-first therapy in this population.

How to Verify Coverage for a Specific Centene Plan

Coverage details change at each plan year's annual formulary update, typically effective January 1. The most reliable methods for verifying current Forteo coverage under a member's specific Centene plan are:

1. The plan's online formulary lookup tool. Ambetter, WellCare, and Medicaid subsidiary websites each host a drug formulary search function. Entering "teriparatide" or the brand name "Forteo" will display the current tier, PA requirements, and any quantity limits.

2. Calling the pharmacy benefits number on the member's insurance card. A pharmacy benefits representative can confirm specialty pharmacy requirements and the current PA criteria document (sometimes called a "clinical criteria" or "coverage criteria" document).

3. The prescriber's electronic prior authorization system. Most major EHR platforms integrate with CoverMyMeds or PAHub, which pull real-time PA criteria directly from payer databases and allow electronic submission.

4. Contacting Lilly's reimbursement support line (1-866-545-5702 as of the date of this article). Lilly employs dedicated reimbursement specialists who can identify formulary status and initiate the PA process on the prescriber's behalf.

Centene's Medicaid formularies are also subject to state Medicaid agency oversight. Many states publish their complete PDL online through their Medicaid agency website, which provides a secondary verification source independent of the managed care organization [30].